LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) has been assigned an average rating of "Buy" from the seven analysts that are presently covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $35.40.
Several brokerages have weighed in on LENZ. Raymond James assumed coverage on shares of LENZ Therapeutics in a research note on Friday, September 27th. They set an "outperform" rating and a $37.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $38.00 target price on shares of LENZ Therapeutics in a research report on Thursday, November 7th. Piper Sandler reissued an "overweight" rating and set a $36.00 price target on shares of LENZ Therapeutics in a research report on Thursday, August 15th. Finally, William Blair raised shares of LENZ Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th.
Read Our Latest Stock Analysis on LENZ
Institutional Investors Weigh In On LENZ Therapeutics
Several hedge funds have recently added to or reduced their stakes in LENZ. American International Group Inc. bought a new position in LENZ Therapeutics during the first quarter worth $44,000. SG Americas Securities LLC bought a new position in shares of LENZ Therapeutics in the third quarter worth $107,000. Squarepoint Ops LLC purchased a new stake in LENZ Therapeutics in the 2nd quarter worth approximately $181,000. MetLife Investment Management LLC purchased a new stake in shares of LENZ Therapeutics during the 3rd quarter valued at $182,000. Finally, GSA Capital Partners LLP bought a new stake in shares of LENZ Therapeutics in the 3rd quarter worth approximately $246,000. 54.32% of the stock is currently owned by institutional investors and hedge funds.
LENZ Therapeutics Stock Performance
LENZ stock traded down $0.74 during trading hours on Wednesday, hitting $33.91. The company's stock had a trading volume of 94,478 shares, compared to its average volume of 137,033. The stock has a 50 day moving average price of $26.48 and a two-hundred day moving average price of $22.20. LENZ Therapeutics has a 12 month low of $14.42 and a 12 month high of $38.93.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.09. During the same quarter last year, the business posted ($1.33) EPS. As a group, equities analysts anticipate that LENZ Therapeutics will post -2.09 EPS for the current fiscal year.
About LENZ Therapeutics
(
Get Free ReportLENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Featured Articles
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
